August 10, 2010

FDA Pharmaceutical Approval: Zuplenz


FDA Approves Strativa Pharmaceuticals’ Zuplenz (ondansetron) Oral Soluble Film for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting.

“The FDA approval of Zuplenz marks an important milestone for Strativa as it reinforces our commitment to enhancing prescription products to meet the different needs of patients,” said John A. MacPhee, President, Strativa Pharmaceuticals. “Zuplenz offers an innovative and convenient, easy-to-take formulation for patients who have trouble swallowing tablets, while providing the trusted efficacy expected from ondansetron.”

For more information regarding Pharmaceutical Naming or Brand Development, contact Vince Budd at vbudd@addisonwhitney.com

Post a Comment

Your email address will not be published. Required fields are marked *

*